Reviewer's report

**Title:** Bupropion for the treatment of SSRI refractory trichotillomania

**Version:** 1 **Date:** 9 April 2011

**Reviewer:** Vasudeo Paralikar

Which of the following following best describes what type of case report this is?: Other

If other, please specify:

Use of Bupropion for trichotillomania has been rarely reported. Considering trichotillomania as a form of an addictive behavior can be regarded as "Findings that shed new light on the possible pathogenesis of a disease", in view of the excellent therapeutic response on Bupropion.

**Has the case been reported coherently?:** Yes

**Is the case report authentic?:** Yes

**Is the case report ethical?:** Yes

**Is there any missing information that you think must be added before publication?:** Yes

**Is this case worth reporting?:** Yes

**Is the case report persuasive?:** Yes

**Does the case report have explanatory value?:** Yes

**Does the case report have diagnostic value?:** No

**Will the case report make a difference to clinical practice?:** Yes

**Is the anonymity of the patient protected?:** Yes

**Comments to authors:**

Possible role of the synergistic effect of cognitive behavior therapy need to be discussed.

Bloch et al ('et al' separate words) on p.3 and Lochner et al (p.4) need to be referred in References section.
Dannon et al (p.4) to be followed by reference no. in parantheses.

'esp.' should be spelt out as 'especially'.

**Quality of written English:** Needs some language corrections before being published

**Declaration of competing interests:**

I declare that I have no competing interests.